GlassScriptPhysician profile
Sushil Rattan
NPI 1467427120
$2,838.53
in general payments reported to CMS, 2019-2025
19 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $166 · 2022: $43.77 · 2023: $144 · 2024: $625 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.22 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $634.25 | 2020-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $383.48 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $363.00 | 2019-2025 | Entyvio, Eohilia |
| Abbvie INC. | $235.19 | 2019-2025 | |
| Celgene Corporation | $214.35 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $200.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $164.24 | 2025 | Ibsrela |
| Pfizer INC. | $151.50 | 2024-2025 | |
| Gilead Sciences, INC. | $83.72 | 2019-2024 | |
| Celltrion USA INC. | $78.75 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $69.66 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $56.52 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $54.82 | 2025 | Zenpep |
| Shionogi INC | $50.28 | 2019 | |
| Ferring Pharmaceuticals INC. | $30.63 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $26.72 | 2024 | Bylvay |
| Capsovision, INC. | $15.09 | 2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $14.31 | 2019 | |
| Braintree Laboratories, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushil Rattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.